Delving into the Latest Updates on Rhone-Poulenc Rorer Ltd. with Synapse

概览

关联

8

项与 Rhone-Poulenc Rorer Ltd. 相关的药物

RP-23618

靶点

CCL5

作用机制

CCL5抑制剂

在研机构-

原研机构

Aventis Pharma SARL

在研适应症-

非在研适应症

关节炎 [+2]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

RPR-110173

靶点

Coagulation factor x GP IIb/IIIa

作用机制

凝血因子抑制剂 [+1]

在研机构-

原研机构

Rhone-Poulenc Rorer Ltd.

在研适应症-

非在研适应症

血栓栓塞

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

RP-66784

靶点

Kv7.2 x Potassium channel

作用机制

Kv7.2激动剂 [+1]

在研机构-

原研机构

Sanofi

在研适应症-

非在研适应症

心绞痛 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Rhone-Poulenc Rorer Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Rhone-Poulenc Rorer Ltd. 相关的专利（医药）

登录后查看更多信息

49

项与 Rhone-Poulenc Rorer Ltd. 相关的文献（医药）

2008-06-28·Clinical and Experimental Immunology

Inhibition of gene expression by anti-sense oligodeoxynucleotides

Review

作者: ZHENG, R Q H ; KEMENY, D M

Since first proposed by Zamencik & Stephenson in 1978 [1], anti-sense oligodeoxynucleotides (ODN) have been successfully used to inhibit/block the expression of specific genes. This process relies on the ability of an ODN to bind a complementary sequence of messenger ribonucleic acid (mRNA) and so prevent its translation [2]. The mechanism is believed to operate through steric hindrance, by RNase H-like cleavage, or through a combination of both [3]. In addition, formation of triplex DNA via Hoogsteen or reverse-Hoogsteen binding may also have 'anti-gene' activity [4,5]. In the last few years there has been increasing interest in technology which allows researchers to address questions about gene function, to inhibit specific intracellular molecules and to temporarily block specific gene effects without the need for 'knock-out' mice or neutralizing antibodies [6]. This technology may lead to new therapeutic approaches to the treatment of human diseases at a molecular level, and trials are in progress to evaluate their potential for clinical use [7-9]. There are many advantages to anti-sense therapy [2,6,10]. Provided that the relevant gene sequences are known, there is very wide choice of gene targets, including intracellular, membrane-bound and soluble molecules of mammalian cells, bacteria and viruses. In this issue of Clinical and Experimental Immunology, Ikizawa et al. [11] describe the use of ODN to block IL-4 receptor expression and IgE synthesis by peripheral blood B cells. This editorial assesses ODN and their therapeutic potential.

2003-02-01·The Journal of Organic Chemistry2区 · 化学

An Asymmetric Synthesis of Aza Analogues of the Tricyclic Skeleton of Daphnane and the ABC Ring System of Phorbol

2区 · 化学

Article

作者: Pink, Jennifer H. ; Hursthouse, Michael B. ; Marson, Charles M. ; Smith, Christopher ; Malik, Abdul ; Hall, David

An asymmetric synthesis of aza analogues of the ABC ring system of phorbol and related compounds containing the 5-7-6-fused framework of daphnane involved construction of the central seven-membered ring by a regioselective reduction of a chiral imide and cyclization with trifluoromethanesulfonic acid. Subsequent demethylation and oxidative dearomatization of ring C afforded an enantiopure dienone 20 with the same relative and absolute configuration at the 9- and 10-positions of the phorbol skeleton.

2001-01-01·Synlett

N-(1′-Benzotriazolylmethyl)-5-phenylmorpholin-2-one: A Stable Crystalline Chiral Azomethine Ylid Precursor

作者: Harwood, Laurence M. ; Thurairatnam, Sukanthini ; Aldous, David J. ; Hamelin, Estelle M.-N.

The crystalline adduct (I) of (5S)-5-phenylmorpholin-2-one with formaldehyde and benzotriazole, on treatment with acid, generates an azomethine ylide which can be trapped with a range of dipolarophiles in yields superior to those using in situ generation methodol.

100 项与 Rhone-Poulenc Rorer Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Rhone-Poulenc Rorer Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年06月01日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

8

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

RP-23618 ( CCL5 )	关节炎更多	终止
RP-66784 ( Kv7.2 x Potassium channel )	高血压更多	无进展
RPR-105227 ( endothelin receptor )	高血压更多	无进展
RPR-200765A ( p38 MAPK )	类风湿关节炎更多	无进展
RPR-110173 ( Coagulation factor x GP IIb/IIIa )	血栓栓塞更多	无进展